Evidence map›Paper›PMID 33269456›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2021

Prognostic Impact and Utility of Immunoprofiling in the Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC).

Mary Garland-Kledzik, Abhineet Uppal, Yalda B Naeini, Stacey Stern, Richard Erali, Anthony J Scholer, Adam M Khader, Juan A Santamaria-Barria, Kathleen Cummins-Perry, Yi Zhou and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Focus onCancers · 2024
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Mary Garland-KledzikJohn Wayne Cancer Institute, Providence St. John's Medical Center, 2200 Santa Monica Boulevard, Santa Monica, CA, USA.ORCID 0000-0002-8346-4024
Abhineet UppalJohn Wayne Cancer Institute, Providence St. John's Medical Center, 2200 Santa Monica Boulevard, Santa Monica, CA, USA.
Yalda B NaeiniSt. John's Providence Health System, Santa Monica, CA, USA.
Stacey SternJohn Wayne Cancer Institute, Providence St. John's Medical Center, 2200 Santa Monica Boulevard, Santa Monica, CA, USA.
Richard EraliWake Forest University, Winston-Salem, NC, USA.
Anthony J ScholerJohn Wayne Cancer Institute, Providence St. John's Medical Center, 2200 Santa Monica Boulevard, Santa Monica, CA, USA.
Adam M KhaderJohn Wayne Cancer Institute, Providence St. John's Medical Center, 2200 Santa Monica Boulevard, Santa Monica, CA, USA.
Juan A Santamaria-BarriaJohn Wayne Cancer Institute, Providence St. John's Medical Center, 2200 Santa Monica Boulevard, Santa Monica, CA, USA.
Kathleen Cummins-PerryWake Forest University, Winston-Salem, NC, USA.
Yi ZhouWake Forest University, Winston-Salem, NC, USA.
Konstantinos I VotanopoulosWake Forest University, Winston-Salem, NC, USA.
Perry ShenWake Forest University, Winston-Salem, NC, USA.
Edward A LevineWake Forest University, Winston-Salem, NC, USA.
Anton J BilchikJohn Wayne Cancer Institute, Providence St. John's Medical Center, 2200 Santa Monica Boulevard, Santa Monica, CA, USA. BilchikA@JWCI.org.
Saint John's Health Center · USWake Forest University · USProvidence College · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197
6 · The paper itself

Abstract

backgroundRecent studies have shown an association in non-metastatic colorectal cancer between patient survival and immunoprofiling (expression of CD3, CD4, CD8, CD45, and FOXP3 T cells at the invasive margin (IM) and the tumor center (TC)) regardless of stage. Patients with peritoneal carcinomatosis have a dismal prognosis, but survival can be significantly improved in selected patients who undergo cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). However, current patient selection for CRS/HIPEC is suboptimal. The purpose of this study is to evaluate immune profiles of patients with peritoneal carcinomatosis and their correlation with overall survival (OS).

methodsThe study cohort included patients from a prospectively maintained database of adults with colorectal peritoneal carcinomatosis who underwent CRS/HIPEC. Immunohistochemistry (IHC) using antibodies to CD3, CD4, CD8, CD45RO, and FOXP3 T cells was performed. IHC image density was calculated using ImageJ software, and an immunoscore was determined.

resultsEighty tumors were evaluated from 66 patients. These included 14 primary sites and 66 metastatic sites. R0/R1 resection was achieved in 44 (66.7%) patients. Known prognostic factors including resection status (HR 1.99, p = 0.004) and lymph node status (HR 3.49, p = 0.002) were associated with overall survival. On multivariate analysis, increased CD3/CD4 IM (HR 0.54, p = 0.03) ratio positively was associated with improved OS. DISCUSSION: This is the first study to assess the utility of subtypes of T cells as prognostic markers in patients with colorectal peritoneal carcinomatosis, which may play a role in patients with low-volume disease. Further studies into immune mechanisms may improve patient selection for cytoreductive surgery and HIPEC as well as provide novel pathways for effective immunotherapy.

Indexed as

Colorectal NeoplasmsHyperthermia, InducedPeritoneal NeoplasmsAdultAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyCytoreduction Surgical ProceduresHumansPatient SelectionPrognosisHIPECImmune profilingPeritoneal carcinomatosis

Identifiers

PMID33269456
PMCPMC8936024
OpenAlexW3106808136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.